BioDuro in AI drug discovery deal

US CRDMO BioDuro has formed a strategic collaboration with artificial intelligence (AI)-based drug discovery software firm Atombeat.  Under this, the company will generate vast libraries of potential peptide compounds with Atombeat’s Hermite software and use the RiDymo platform to filter and prioritise them, based on key developability traits such as membrane permeability. It will then apply its high-throughput synthesis capability to produce hundreds of compounds in parallel. 

“In one week, the team could deliver high-purity peptides — ready for biological testing — without purification steps needed,” the firm stated. “Coupled with readily available biology assays, this seamless integration of in silico design and wet-lab validation significantly accelerates R&D timelines while reducing costs and risks.”